Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
14 Dec 2017
Change (% chg)

$-0.04 (-4.71%)
Prev Close
$0.85
Open
$0.86
Day's High
$0.89
Day's Low
$0.81
Volume
17,312
Avg. Vol
69,728
52-wk High
$3.88
52-wk Low
$0.43

Summary

Name Age Since Current Position

J. David Hansen

65 2015 Chairman of the Board, President, Chief Executive Officer

Gregory Hanson

70 2014 Chief Financial Officer

Philip Livingston

74 2014 Chief Science Officer, Director

Paul Maffuid

61 2014 Vice President - Pharmaceutical Development and Operations

Paul Resnick

60 2016 Vice President and Chief Business Officer

Jeffrey Eisenberg

51 2016 Director

Kenneth Cohen

61 2014 Independent Director

Robert Hoffman

51 2014 Independent Director

Paul Maier

69 2014 Independent Director

Thomas Varvaro

47 2015 Independent Director

Jenene Thomas

2017 IR Contact Officer

Biographies

Name Description

J. David Hansen

Mr. J. David Hansen is Chairman of the Board, President, Chief Executive Officer of the Company. He has served as MabVax’s President, Chief Executive Officer, and Member of its Board of Directors since co-founding MabVax in 2006. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience. He has held senior management roles in both private start-up companies as well as small to mid-sized public companies. His senior level experience includes executive Mr. Hansen has executed a wide variety of in and out licensing agreements, research and development collaborations, joint ventures, divestitures, and acquisitions. Mr. Hansen has developed expertise in the therapeutic areas of immunology, oncology, and infectious disease. From 1998 to 2006, Mr. Hansen was a corporate officer of Avanir Pharmaceuticals. He held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences. From 1989 to 1999 Mr. Hansen served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development. He has additional management experience with Merck & Co. (Schering- Plough), Key Pharmaceuticals, and Bristol Myers Squibb.

Gregory Hanson

Mr. Gregory P. Hanson is Chief Financial Officer of Mabvax Therapeutics Holdings, Inc. and, prior to the merger, joined MabVax in February of 2014 as its Chief Financial Officer. Mr. Hanson is an experienced CFO and was a Managing Director of First Cornerstone, starting in 2008 until February 2014, a board and management advisor to companies and executives in the areas of international corporate development, financing strategies, commercialization of technologies and products, and M&A advisory services. Since November 2009, Mr. Hanson has served as Advisory Board Member of Menon International, Inc. in an international capacity advising on partnering and licensing arrangements, financings, and in commercializing technologies involving biosensor devices and assays, and renewable products. Since October 2011, Mr. Hanson has served on the Life Sciences Advisory Board of Brinson Patrick Securities, a boutique investment bank, and continues to serve from time to time as a confidential advisor to several other tech and life sciences companies. Mr. Hanson is the 2012-2013 President and 8-year Board Member of San Diego Financial Executives International (FEI), and has served on the Capital Formation Committee at BIOCOM since 2011. Mr. Hanson is a Certified Management Accountant and has an MBA with distinction from the University of Michigan, a BS in Mechanical Engineering from Kansas State University, and Series 7 and Series 63 securities.

Philip Livingston

Dr. Philip O. Livingston, M.D is a member of Board of Directors and Chief Science Officer of Mabvax Therapeutics Holdings, Inc, and, prior to the merger, served as a member of MabVax’s Board of Directors and its Chief Science Officer since 2012. He received his MD degree from Harvard Medical School and was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University and Attending Physician and Member in Memorial Sloan-Kettering Cancer Center where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years until his retirement from MSKCC October 1, 2011. Dr. Livingston’s research focused on: identification of suitable targets for immunotherapy of a variety of cancers, construction of polyvalent conjugate vaccines specifically designed to augment antibody responses against these targets, and identification of optimal immunological adjuvants to further augment the potency of these vaccines. He has over 150 publications and 4 issued and 3 pending patents concerning cancer vaccines. Recently, Dr. Livingston helped establish MabVax Therapeutics, Inc., and another biotech company, Adjuvance Technologies, Inc. MabVax supports two randomized Phase II trials with these MSKCC polyvalent vaccines and establishment of human monoclonal antibodies from the blood of immunized patients.

Paul Maffuid

Dr. Paul W. Maffuid, Ph.D., is Vice President of the Company. Dr. Maffuid joined MabVax Therapeutics in July of 2014 from AAIPHARMA Services Corporation where he was Executive Vice President, Pharma Operations. His responsibilities included formulation, process development, technology transfer, stability and analytical services for clients developing biologic and small molecule therapeutics. He was a member of the Executive Team that transformed a declining business into one of the world’s leading providers of integrated development services for the biopharmaceutical sector. He joined AAIPHARMA in 2011 after founding and managing Biopharmalogics, Inc. a consulting service providing Chemistry Manufacturing and Controls (CMC) as well as Drug Metabolism-Pharmacokinetics (DMPK) services for the development of pharmaceutical products since 2008. Prior to that Dr. Maffuid was Senior Vice President of Irvine Pharmaceutical Services, Inc. from 2008 to 2009. From 2001 to 2008 he was Vice President of Pharmaceutical Development for Arena Pharmaceuticals. At Arena Dr. Maffuid was a member of the Executive Management team responsible for all CMC and DMPK in support of discovery, development, and commercial operations. He led the design and construction of a 40,000 sq-ft cGMP compliant pilot manufacturing facility. Dr. Maffuid had management roles at Magellan Laboratories, Cabrillo Laboratories, and Amylin Pharmaceuticals.

Paul Resnick

Dr. Paul Resnick is Vice President and Chief Business Officer of the Company. He is an experienced biopharmaceutical executive with over 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration. FromJanuary 2013toMarch 2016, Dr. Resnick was Senior Vice President, for Juventas Therapeutics where he was responsible for business and commercial strategy and working with executive management overseeing clinical development and financial and business strategies. FromJanuary 2008toJanuary 2012he was Vice President, Business Development and member of the executive management team for Intellikine, Inc. (acquired by Takeda Pharmaceuticals), responsible for managing alliances and leading the business development strategy that resulted in securing an acquisition by Takeda Pharmaceuticals. Earlier in his career Dr. Resnick held Director and Senior Director positions at Pfizer, Rinat Neuroscience (acquired by Pfizer), Intermune, Inc. and Roche Pharmaceuticals. Dr. Resnick earned a Doctor of Medicine from The Medical College of Wisconsinand a Master of Business Administration from The Wharton School of the University of Pennsylvania.

Jeffrey Eisenberg

Mr. Jeffrey F. Eisenberg is Director of the Company. From 2009 to January 2016 Mr. Eisenberg served as President, Chief Executive Officer and board member of Noven Pharmaceuticals, Inc. Noven develops, manufactures and markets prescription pharmaceuticals, with a specialty in transdermal drug delivery systems. Noven is the U.S. prescription pharmaceutical division of Hisamitsu Pharmaceutical Inc., a Japanese pharmaceutical company and the world's largest manufacturer of transdermal drug patches. Mr. Eisenberg had been part of Noven's senior management team since 1998, having previously served as Executive Vice President, Senior Vice President - Strategic Alliances, and as the company's General Counsel and Corporate Secretary. Mr. Eisenberg also served as President of Novogyne Pharmaceuticals, a Women's Health commercial joint venture between the Noven and Novartis Pharmaceuticals Corporation. Mr. Eisenberg has significant experience in the area of corporate transactions and strategic alliances, product development, commercialization, manufacturing and talent management. In addition, he led the post-acquisition integration of JDS Pharmaceuticals, a private specialty pharmaceutical company purchased by Noven in 1997, as well as the integration of Noven and Hisamitsu following the acquisition of Noven. Mr. Eisenberg is an expert in corporate governance, having advised the boards of IVAX, Noven and others through a number of significant internal and external issues, including mergers and acquisitions, corporate financings, strategic alliances, CEO transitions, securities class action lawsuits, FDA warning letters and consent decrees, and development and implementation of corporate governance policies. Mr. Eisenberg holds a BS in Economics from the Wharton School of the University of Pennsylvania, and a JD from Columbia University Law School.

Kenneth Cohen

Mr. Kenneth M. Cohen is Director of the Company., effective July 8, 2014. He has served as a member of the Board of Directors of Adamis Pharmaceuticals Corporation (a public pharmaceutical company) since January 2011. He is an advisor to companies, entrepreneurs and investors in the life sciences area. He was a co-founder of publicly held Somaxon Pharmaceuticals and served as its President and Chief Executive Officer from August 2003 through December 2007 and continued as a director until June 2008. Previously, he was an independent advisor to various biotechnology and pharmaceutical companies, entrepreneurs and investors, including Synbiotics Corporation, Applied NeuroSolutions, Inc. and Highbridge Capital Management. From May 1996 to April 2001, he was President and Chief Executive Officer of Synbiotics Corporation, a diagnostics company. From March 1995 to February 1996, Mr. Cohen was Executive Vice President and Chief Operating Officer for Canji Incorporated, a human gene-therapy company, until its acquisition by Schering-Plough Corporation in February 1996. Prior to joining Canji, he was Vice President of Business Affairs at Argus Pharmaceuticals, Inc. and Vice President of Marketing and Business Development for LifeCell Corporation. He served as a member of the Board of Directors of Adamis Pharmaceuticals Corporation (a public pharmaceutical company) from January 2011 until August 2014. Mr. Cohen began his career at Eli Lilly and Company in 1978, where, among many different responsibilities over ten years, he directed business planning for the Medical Instrument Systems Division and managed the launch of Prozac. He received an A.B. in biology and chemistry from Dartmouth College and an M.B.A. from the Wharton School of The University of Pennsylvania.

Robert Hoffman

Mr. Robert E. Hoffman is a Director since September of 2014 of Mabvax Therapeutics Holdings, Inc., and since June of 2012, Mr. Hoffman has served the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, or Arena. Mr. Hoffman previously served as Arena’s Vice President, Finance and Chief Financial Officer from August 2011 to June 2012 and from December 2005 to March 2011, as it is Vice President, Finance and Chief Accounting Officer from June 2004 to December 2005, as its Vice President of Finance from April 2000 to June 2004; and as its Controller from August 1997 to April 2000. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr. Hoffman is currently a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company and Kura Oncology, Inc. a biopharmaceutical company. He also currently serves as a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. In addition, Mr. Hoffman is a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.

Paul Maier

Mr. Paul V. Maier is Director of Mabvax Therapeutics Holdings, Inc. He served as the Chief Financial Officer of Sequenom, Inc., (a public biotechnology company) from June of 2009 through June of 2014. Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Since 2007, Mr. Maier has served as a member of the Board of Directors of International Stem Cell Corporation (a public life sciences company) and currently services as the Chairperson of its Audit Committee and as a member of its Compensation and Governance Committees. Mr. Maier also serves as Chairman of the Audit Committee and a member of the Governance Committee of the Board of Directors of Apricus Biosciences, Inc (a public pharmaceutical company) Mr. Maier also serves as a Director of Biological Dynamics and Ritter Pharmaceuticals, both private life science companies. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.

Thomas Varvaro

Mr. Thomas C. Varvaro is Director of the Mabvax Therapeutics Holdings, Inc. He has served as the ChromaDex Corp. (OTCQX: CDXC) Chief Financial Officer since January 2004 and Secretary since March 2006. He also served as a director of ChromaDex Corporation from March 2006 until May 2010. Mr. Varvaro is responsible for overseeing all of ChromaDex Corporation’s aspects of accounting, information technology, Intellectual Property management and human resources management. Mr. Varvaro has extensive process mapping and business process improvement skills, along with a solid information technology background that includes management and implementation experiences ranging from custom application design to enterprise wide system deployment. Mr. Varvaro also has hands-on experience in integrating acquisitions and in new facility startups. In working with manufacturing organizations Mr. Varvaro has overseen plant automation, reporting and bar code tracking implementations. Mr. Varvaro also has broad legal experience in intellectual property (IP), contract and employment law. From 1998 to 2004, Mr. Varvaro was employed by Fast Heat Inc., a Chicago, Illinois based Global supplier to the plastics, HVAC, packaging, and food processing industries, where he began as controller and was promoted to chief information officer and then chief financial officer during his tenure. During his time there Mr. Varvaro was responsible for all financial matters including accounting, risk management and human resources. From 1993 to 1998, Mr. Varvaro was employed by Leaf Bakery, Inc., Chicago, Illinois, during its rise to becoming a national leader in specialty products. During his tenure Mr. Varvaro served in information technology and accounting roles, helping to shepherd the company from a single facility to national leader in specialty food products. Mr. Varvaro has a B.S. in Accounting from University of Illinois, Urbana-Champaign and has been certified as a Certified Public Accountant.

Jenene Thomas

Basic Compensation